API
< Back to all clusters
[HEALTH] · 2 sources

started · updated

Elafibranor shows positive results in Phase III PBC clinical trials

Results from the Phase III ELSPIRE trial, published in the journal HEPATOLOGY, indicate that elafibranor significantly improves disease markers for patients with primary biliary cholangitis (PBC). The study focused on patients who had an incomplete response or intolerance to first-line therapy, ursodeoxycholic acid (UDCA). At week 52, 85.3% of patients treated with elafibranor achieved alkaline phosphatase (ALP) normalization, compared to 23.3% in the placebo group.

Additional data from the open-label extension of the ELATIVE trial showed that elafibranor sustained biochemical responses for up to four years. While biochemical response rates were numerically lower in patients with advanced disease compared to those with early-stage disease, noninvasive tests of fibrosis remained stable across both groups. The treatment was reported to be well tolerated with no new safety signals identified during the trials.

Entities

American Association for the Study of Liver Diseases · Elafibranor · UT Southwestern Medical Center